ClinicalTrials.gg
CompletedNCT06892691PERFECT-MPEUpdated Oct 5, 2026

Pleuroscopy First Versus Thoracentesis First in Patients With Suspected Malignant Pleural Effusions

An interventional study of Pleuroscopy first and Thoracentesis first in Pleural Effusion and Cancer, sponsored by Icahn School of Medicine at Mount Sinai. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Icahn School of Medicine at Mount Sinai · Not applicable, Interventional, and Diagnostic

How we know

Updated Oct 5, 2026Now CompletedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Pleural Effusion with a site in United States — 6 open to participants now, 9 under way, none of them phase 3. Pleural Effusion · United States.

Enrollment
15th of 34
75 · median 42
Started
2025
with 4 others
No phase
18 of 45
3 open now
Registered
41st of 45
by date
Lead sponsor
2 of 45
Icahn School of Medicine at Mount Sinai

Among the 45 studies in Pleural Effusion with a site in United States, this one is the 15th largest by enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2025, is one of 18 with no phase, and was the 41st registered.

Pleural Effusion

241 studies on the registry are indexed under Pleural Effusion; 49 are open to participants now.

Browse Pleural Effusion studies →

Open to participants now

6 of the 45 studies in Pleural Effusion with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Pleural Effusion studies recruiting now, 25 (83%) set no upper age limit and 2 (7%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Pleural Effusion with a site in United States, or all of them as a file.
02

Study summary

This is a randomized control trial of patients with suspected malignant pleural effusions to compare whether patients who have a thoracentesis or pleuroscopy (pleural biopsy) obtain an adequate biopsy, achieve a diagnosis, and begin cancer-directed therapy faster.

Read the detailed description

This is a randomized control trial of patients with suspected malignant pleural effusions comparing patients who undergo either pleuroscopy or thoracentesis as the first diagnostic test. Both procedures are considered standard of care for this diagnosis but it is unknown which one provides more adequate biopsy samples and achieves faster diagnosis and shorter time to oncologic treatment. Currently, most patients undergo thoracentesis first and, if this is inadequate for diagnosis, they then undergo pleuroscopy for further biopsy samples. This study seeks to assess whether patients who undergo pleuroscopy as the first test obtain adequate biopsy samples and a faster path to further oncologic care compared to patients who undergo thoracentesis first. Patients will be recruited and randomized in a 1:1 manner.

Ultrasound is routinely used prior to the procedure and a chest x-ray is done after the procedure. Any other imaging will be determined by clinic need only. No imaging will be done for research purposes. No additional samples will be collected other than what is necessary for diagnostic purposes. In patients who have a non-diagnostic thoracentesis, the participants will be referred for pleuroscopy as the next diagnostic step. In the rare case that pleuroscopy does not achieve adequate diagnosis, the next step would be a liquid biopsy (non-invasive serologic testing for oncologic markers.) The need for liquid biopsy in participants in this study will be determined on a case-by-case basis depending on the clinical concern for malignancy.

03

Conditions studied

  • Pleural Effusion
  • Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Referral for diagnostic pleural procedure.
  • Age ≥ 18 years.
  • Suspected malignant pleural effusion (Suggestive radiologic appearance (based on computed tomography or positron emission tomography) OR suspected cancer with associated effusion.)

Exclusion criteria

Exclusion Criteria:

  • Inability to provide .
  • Needs emergent drainage.
  • Pleural effusion is known to be malignant.
  • Suspected transudative, infectious or inflammatory effusion etiology.
  • Having prior inconclusive/non-diagnostic thoracentesis or pleuroscopy.
  • Patient is deemed by the clinical team to be more appropriate for VATS .
  • Terminally ill patients in whom a diagnosis will not change management, or who is unlikely to be a candidate for oncological treatment due to significant comorbidities.
  • Pregnancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (actual)

Study arms

  • Active comparator
    Pleuroscopy first

    Participants will undergo pleuroscopy first

    Procedure: Pleuroscopy first

  • Active comparator
    Thoracentesis first

    Participants will undergo thoracentesis first

    Procedure: Thoracentesis first

Interventions

  • ProcedurePleuroscopy first

    Pleuroscopies are performed under moderate sedation with local anesthesia. Through a 1-cm incision a camera is introduced into the pleural space and the space is inspected after draining all fluid. Targeted biopsies under direct visualization are obtained using forceps. The aspirated fluid and biopsies obtained are sent to the cytology and pathology laboratories for analysis.

  • ProcedureThoracentesis first

    Thoracenteses are performed under local anesthesia with the insertion of a 5-8Fr catheter into the pleural space. The aspirated fluid obtained is sent to the cytology laboratory for analysis.

06

What researchers measure

Primary outcomes

  1. Proportion of biopsies adequate for definitive diagnosis

    Proportion of biopsies adequate for definitive diagnosis

    Time frame: 6 months

Secondary outcomes

  1. Time from initial visit with pulmonologist to procedure

    Time from initial visit with pulmonologist to procedure

    Time frame: 6 months

  2. Time from initial procedure to diagnosis

    Time from initial procedure to diagnosis

    Time frame: 6 months

  3. Time from initial visit with pulmonologist to diagnosis

    Time from initial visit with pulmonologist to diagnosis

    Time frame: 6 months

  4. Time from initial visit with pulmonologist to seeing oncologist

    Time from initial visit with pulmonologist to seeing oncologist

    Time frame: 6 months

  5. Time from initial visit with pulmonologist to starting treatment

    Time from initial visit with pulmonologist to starting treatment

    Time frame: 6 months

  6. Time from seeing oncologist to starting treatment

    Time from seeing oncologist to starting treatment

    Time frame: 6 months

  7. Frequency of procedure-related complications

    Frequency of procedure-related complications

    Time frame: 6 months

  8. Frequency of additional diagnostic testing

    Frequency of additional diagnostic testing

    Time frame: 6 months

07

Study locations

2 sites
  • Mount Sinai West
    New York, New York 10019, United States
  • Mount Sinai Hospital
    New York, New York 10029, United States
08

References and documents

Individual participant data

Plan to share: Yes — All of the individual participant data collected during the trial, after deidentification.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Immediately following publication. No end date.

Access criteria: Investigators whose proposed use of the data has been approved by an independent review committee ('learned intermediary') identified for this purpose. Any purpose. Proposals should be directed to udit.chaddha@mssm.edu. To gain access, data requestors will need to sign a data access agreement. Data are available for 5 years at a third party website (Link tbd).

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Aug 2026, 17 months.

Of 61 non-industry interventional studies with no phase under Pleural Effusion, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 52. This study's 17 months is below that.

Counting every sponsor, half of 63 studies reached it within 26 months; a quarter within 16 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Sep 2026 → Aug 2026 and completion Sep 2026 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2025
First posted
Mar 25, 2025
StartActual
Mar 19, 2025
Primary completionActual
Aug 30, 2026was Sep 2026
CompletionActual
Aug 30, 2026was Sep 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 5, 2026
Start date
Mar 24, 2025→Mar 19, 2025
Oct 5, 2026
Primary completion
Sep 17, 2026→Aug 30, 2026 (actual)
Oct 5, 2026
Study completion
Sep 17, 2026→Aug 30, 2026 (actual)
Oct 5, 2026
Enrollment
98 (estimated)→75 (actual)
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Recruiting→Completed
    Start date Mar 24, 2025→Mar 19, 2025
    Primary completion Sep 17, 2026→Aug 30, 2026 (now actual)
    Study completion Sep 17, 2026→Aug 30, 2026 (now actual)
    Enrollment 98 (estimated)→75 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06892691
Responsible party
Udit Chaddha (Associate Professor of Medicine and Thoracic Surgery, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Mar 25, 2025
Start date
Mar 19, 2025
Primary completion
Aug 30, 2026
Completion
Aug 30, 2026
Last update
Oct 5, 2026

Study contacts

Udit Chaddha, MBBS
principal investigator · MOUNT SINAI HOSPITAL

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion